121 related articles for article (PubMed ID: 38466206)
21. Repeated triamcinolone acetonide injection in the treatment of upper-lid retraction in patients with thyroid-associated ophthalmopathy.
Xu D; Liu Y; Xu H; Li H
Can J Ophthalmol; 2012 Feb; 47(1):34-41. PubMed ID: 22333849
[TBL] [Abstract][Full Text] [Related]
22. The success rate of TED upper eyelid retraction reoperations.
Golan S; Rootman DB; Goldberg RA
Orbit; 2016 Dec; 35(6):335-338. PubMed ID: 27560939
[TBL] [Abstract][Full Text] [Related]
23. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
[TBL] [Abstract][Full Text] [Related]
24. Nonsurgical management of upper eyelid margin asymmetry using hyaluronic acid gel filler.
Mancini R; Khadavi NM; Goldberg RA
Ophthalmic Plast Reconstr Surg; 2011; 27(1):1-3. PubMed ID: 20551854
[TBL] [Abstract][Full Text] [Related]
25. Reactivation After Teprotumumab Treatment for Active Thyroid Eye Disease.
Hwang CJ; Rebollo NP; Mechels KB; Perry JD
Am J Ophthalmol; 2024 Jul; 263():152-159. PubMed ID: 38142982
[TBL] [Abstract][Full Text] [Related]
26. Optimizing esthetic outcomes in graded full-thickness anterior blepharotomy for Graves' ophthalmopathy.
Lee JKS; Loi MX; Wei YH; Liao SL
Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1303-1308. PubMed ID: 30941511
[TBL] [Abstract][Full Text] [Related]
27. A modified posterior approach for upper eyelid retraction.
Looi AL; Sharma B; Dolman PJ
Ophthalmic Plast Reconstr Surg; 2006; 22(6):434-7. PubMed ID: 17117096
[TBL] [Abstract][Full Text] [Related]
28. Real-World Experience With Teprotumumab in Patients With Dysthyroid Optic Neuropathy.
Tamhankar MA; Pradeep T; Chen Y; Briceño CA
J Neuroophthalmol; 2024 Mar; 44(1):74-79. PubMed ID: 37751310
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab.
Ho TC; Maamari RN; Kossler AL; Sears CM; Freitag SK; Reshef ER; Shinder R; Rootman DB; Diniz SB; Kahana A; Schlachter D; Do TH; Kally P; Turner S; Mokhtarzadeh A; Harrison AR; Hwang CJ; Kim HJ; Avila SA; Thomas DA; Magazin M; Wester ST; Lee WW; Clauss KD; Holds JB; Sniegowski M; Compton CJ; Briggs C; Malik AI; Lucarelli MJ; Burkat CN; Patel LG; Couch SM
Ophthalmic Plast Reconstr Surg; 2023 Mar-Apr 01; 39(2):150-155. PubMed ID: 36095848
[TBL] [Abstract][Full Text] [Related]
30. Teprotumumab and Orbital Decompression for the Management of Proptosis in Patients With Thyroid Eye Disease.
Hubschman S; Sojitra B; Ghiam S; Sears C; Hwangbo N; Goldberg RA; Rootman DB
Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):270-275. PubMed ID: 37972968
[TBL] [Abstract][Full Text] [Related]
31. Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series.
Chu M; Sung J; Song M; Song A; Song J
J Med Case Rep; 2022 May; 16(1):195. PubMed ID: 35538553
[TBL] [Abstract][Full Text] [Related]
32. Botulinum toxin type a for dysthyroid upper eyelid retraction.
Morgenstern KE; Evanchan J; Foster JA; Cahill KV; Burns JA; Holck DE; Perry JD; Wulc AE
Ophthalmic Plast Reconstr Surg; 2004 May; 20(3):181-5. PubMed ID: 15167723
[TBL] [Abstract][Full Text] [Related]
33. Objective Diplopia Outcomes for Patients Treated With Teprotumumab for Thyroid Eye Disease.
Mudalegundi S; Huang P; Henderson AD; Carey AR
J Neuroophthalmol; 2024 Mar; 44(1):80-86. PubMed ID: 38294416
[TBL] [Abstract][Full Text] [Related]
34. An algorithm for Botulinum toxin A injection for upper eyelid retraction associated with thyroid eye disease: long-term results.
Ozturk Karabulut G; Fazil K; Saracoglu Yilmaz B; Ozturker C; Günaydın ZK; Taskapili M; Kaynak P
Orbit; 2021 Oct; 40(5):381-388. PubMed ID: 32885692
[TBL] [Abstract][Full Text] [Related]
35. A comparison of proptosis reduction with teprotumumab versus surgical decompression based on fat-to-muscle ratio in thyroid eye disease.
Ting MAJ; Topilow NJ; Ediriwickrema LS; Yoon JS; Liu CY; Korn BS; Kikkawa DO
Orbit; 2024 Apr; 43(2):222-230. PubMed ID: 37978819
[TBL] [Abstract][Full Text] [Related]
36. [Acellular xenogenic dermal matrix as a spacer graft for treatment of eyelid retraction related to thyroid associated ophthalmopathy].
Zhuang A; Sun J; Zhang S; Zhou HF
Zhonghua Yan Ke Za Zhi; 2019 Nov; 55(11):821-827. PubMed ID: 31715678
[No Abstract] [Full Text] [Related]
37. Upper eyelid weighting for lagophthalmos results in contralateral upper eyelid elevation.
Karlin JN; Le C; Rootman DB
Orbit; 2022 Aug; 41(4):464-468. PubMed ID: 34229537
[TBL] [Abstract][Full Text] [Related]
38. The Effect of Upper Aging Blepharoplasty on Upper and Lower Eyelid Position.
Park J; Choi B; Baek S
J Craniofac Surg; 2018 May; 29(3):747-750. PubMed ID: 29420375
[TBL] [Abstract][Full Text] [Related]
39. Observations on the Efficacy of Two Methods for the Treatment of Upper Eyelid Retraction in Thyroid-Associated Ophthalmopathy.
Li D; Sun F
Biomed Res Int; 2021; 2021():9514279. PubMed ID: 33791385
[TBL] [Abstract][Full Text] [Related]
40. Analysis of Lid Contour in Thyroid Eye Disease With Upper and Lower Eyelid Retraction Using Multiple Radial Midpupil Lid Distances.
Kang D; Lee J; Park J; Lee H; Park M; Baek S
J Craniofac Surg; 2016 Jan; 27(1):134-6. PubMed ID: 26674885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
